Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of sevasemten in Becker muscular dystrophy
NL-OMON58682Phase 2Completed
- Sponsor
- Edgewise Therapeutics
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Becker muscular dystrophy (BMD) comparing Sevasemten with Placebo (2 arms). Started Dec 2022; status: completed.
02
Drugs
sevasemten
03
Conditions
Becker muscular dystrophy (BMD)
Beyond the preview
Go deeper on NL-OMON58682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58682.